Antivirals for Respiratory Viral Infections: Problems and Prospects.
Identifieur interne : 000C23 ( PubMed/Corpus ); précédent : 000C22; suivant : 000C24Antivirals for Respiratory Viral Infections: Problems and Prospects.
Auteurs : Qiang Liu ; Yuan-Hong Zhou ; Feng Ye ; Zhan-Qiu YangSource :
- Seminars in respiratory and critical care medicine [ 1098-9048 ] ; 2016.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Humans, Middle East Respiratory Syndrome Coronavirus, Respiratory Tract Infections (drug therapy), Respiratory Tract Infections (virology), SARS Virus, Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology).
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : Coronavirus Infections, Respiratory Tract Infections, Severe Acute Respiratory Syndrome.
- virology : Coronavirus Infections, Respiratory Tract Infections, Severe Acute Respiratory Syndrome.
- Animals, Humans, Middle East Respiratory Syndrome Coronavirus, SARS Virus.
Abstract
In the past two decades, several newly emerging and reemerging viral respiratory pathogens including several influenza viruses (avian influenza and pandemic influenza), severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV), have continued to challenge medical and public health systems. Thereafter, the development of cost-effective, broad-spectrum antiviral agents is the urgent mission of both virologists and pharmacologists. Current antiviral developments have focused targets on viral entry, replication, release, and intercellular pathways essential for viral life cycle. Here, we review the current literature on challenges and prospects in the development of these antivirals.
DOI: 10.1055/s-0036-1584803
PubMed: 27486742
Links to Exploration step
pubmed:27486742Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antivirals for Respiratory Viral Infections: Problems and Prospects.</title><author><name sortKey="Liu, Qiang" sort="Liu, Qiang" uniqKey="Liu Q" first="Qiang" last="Liu">Qiang Liu</name><affiliation><nlm:affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Yuan Hong" sort="Zhou, Yuan Hong" uniqKey="Zhou Y" first="Yuan-Hong" last="Zhou">Yuan-Hong Zhou</name><affiliation><nlm:affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</nlm:affiliation></affiliation></author><author><name sortKey="Ye, Feng" sort="Ye, Feng" uniqKey="Ye F" first="Feng" last="Ye">Feng Ye</name><affiliation><nlm:affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Zhan Qiu" sort="Yang, Zhan Qiu" uniqKey="Yang Z" first="Zhan-Qiu" last="Yang">Zhan-Qiu Yang</name><affiliation><nlm:affiliation>State Key Laboratory of Virology, Institute of Medical Virology, School of Medicine, Wuhan University, Wuhan, China.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27486742</idno><idno type="pmid">27486742</idno><idno type="doi">10.1055/s-0036-1584803</idno><idno type="wicri:Area/PubMed/Corpus">000C23</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antivirals for Respiratory Viral Infections: Problems and Prospects.</title><author><name sortKey="Liu, Qiang" sort="Liu, Qiang" uniqKey="Liu Q" first="Qiang" last="Liu">Qiang Liu</name><affiliation><nlm:affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Yuan Hong" sort="Zhou, Yuan Hong" uniqKey="Zhou Y" first="Yuan-Hong" last="Zhou">Yuan-Hong Zhou</name><affiliation><nlm:affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</nlm:affiliation></affiliation></author><author><name sortKey="Ye, Feng" sort="Ye, Feng" uniqKey="Ye F" first="Feng" last="Ye">Feng Ye</name><affiliation><nlm:affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Zhan Qiu" sort="Yang, Zhan Qiu" uniqKey="Yang Z" first="Zhan-Qiu" last="Yang">Zhan-Qiu Yang</name><affiliation><nlm:affiliation>State Key Laboratory of Virology, Institute of Medical Virology, School of Medicine, Wuhan University, Wuhan, China.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Seminars in respiratory and critical care medicine</title><idno type="eISSN">1098-9048</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Humans</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>Respiratory Tract Infections (drug therapy)</term><term>Respiratory Tract Infections (virology)</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Respiratory Tract Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Respiratory Tract Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the past two decades, several newly emerging and reemerging viral respiratory pathogens including several influenza viruses (avian influenza and pandemic influenza), severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV), have continued to challenge medical and public health systems. Thereafter, the development of cost-effective, broad-spectrum antiviral agents is the urgent mission of both virologists and pharmacologists. Current antiviral developments have focused targets on viral entry, replication, release, and intercellular pathways essential for viral life cycle. Here, we review the current literature on challenges and prospects in the development of these antivirals.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27486742</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-9048</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>08</Month></PubDate></JournalIssue><Title>Seminars in respiratory and critical care medicine</Title><ISOAbbreviation>Semin Respir Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Antivirals for Respiratory Viral Infections: Problems and Prospects.</ArticleTitle><Pagination><MedlinePgn>640-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0036-1584803</ELocationID><Abstract><AbstractText>In the past two decades, several newly emerging and reemerging viral respiratory pathogens including several influenza viruses (avian influenza and pandemic influenza), severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV), have continued to challenge medical and public health systems. Thereafter, the development of cost-effective, broad-spectrum antiviral agents is the urgent mission of both virologists and pharmacologists. Current antiviral developments have focused targets on viral entry, replication, release, and intercellular pathways essential for viral life cycle. Here, we review the current literature on challenges and prospects in the development of these antivirals.</AbstractText><CopyrightInformation>Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yuan-Hong</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhan-Qiu</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Institute of Medical Virology, School of Medicine, Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Respir Crit Care Med</MedlineTA><NlmUniqueID>9431858</NlmUniqueID><ISSNLinking>1069-3424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27486742</ArticleId><ArticleId IdType="doi">10.1055/s-0036-1584803</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000C23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27486742
|texte= Antivirals for Respiratory Viral Infections: Problems and Prospects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27486742" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |